Presymptom Health
- Company typePrivate
- Founded2019
- HeadquartersPorton, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
Presymptom Health firmographics
Firmographics- Name
- Presymptom Health
- Legal name
- Presymptom Health Ltd
- Website
- https://presymptom.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Closed
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Presymptom Health industry classification
Industry- Product category
- Sepsis and Infection Diagnostics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Sepsis, Deterioration & Rapid Response CDS (HLACAGAF)
- akta.pro secondary industry
- Risk Stratification, Early Warning Scores & Predictive Analytics (HLACAGAE)
Keywords
Where Presymptom Health is headquartered
LocationHeadquarters
- HQ city
- Porton
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Presymptom Health business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Diagnostic Tests Platform: The company was developing AI-driven diagnostic tests for sepsis and infections. Revenue model would likely involve sale of diagnostic tests to healthcare providers and clinical settings. Pre-commercial stage with UK market entry planned for 2025.
Go-to-market motion1 record
Presymptom Health product offering
Product offeringCore offering
Presymptom Health developed an AI-driven diagnostics platform capable of detecting sepsis and infections up to three days before clinical symptoms manifest. The technology was based on proprietary research originating from the UK Ministry of Defence's Defence Science and Technology Laboratory (Dstl) and was targeted at hospitals, NHS trusts, and clinical healthcare settings. The company was pre-commercial with planned UK market entry in 2025.
Product overview
Presymptom Health developed a single unified AI-driven diagnostics platform for sepsis and infection detection. The platform leveraged research from the Defence Science and Technology Laboratory to analyze patient data and provide early diagnosis up to three days before symptoms manifest. The company was targeting UK market entry in 2025 but is now in Members' Voluntary Liquidation and no longer trading as of April 2026.
Differentiator
Problem solved
Functional benefit
Products and services
- Sepsis and Infection Diagnostics Platform An AI-driven diagnostics platform designed to detect sepsis and infections up to three days before clinical symptoms appear, based on proprietary research from the UK Defence Science and Technology Laboratory. Intended for hospitals, NHS trusts, and clinical healthcare settings to enable earlier clinical intervention, reduce inappropriate antibiotic use, and improve patient outcomes.
Quantifiable outcome
- Diagnoses infections up to three days early compared to conventional methods
Companies that use Presymptom Health
Customer profileSegments1 record
Ideal customer profiles1 record
Presymptom Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature1 record
Presymptom Health partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Defence Science and Technology Laboratory (Dstl)corePresymptom Health was spun out from the UK Ministry of Defence's Defence Science and Technology Laboratory (Dstl). The company's AI-driven diagnostic technology for sepsis and infections is based on research originating from Dstl. This research-based origin provides the foundation for the company's proprietary technology platform.
Scale indicators2 records
Recent moves7 records
Expansion highlights3 records
Presymptom Health competitors and assessment
Company assessmentDirect peers
- Prenosis: Prenosis develops AI-driven predictive diagnostics for sepsis and acute conditions in hospital settings, directly competing with Presymptom's AI-based early sepsis detection platform.
- Dascena: Dascena developed machine-learning models (InSight) for early prediction of sepsis and acute kidney injury from EHR data, mirroring Presymptom's predictive AI approach.
- Accelerate Diagnostics: Accelerate Diagnostics provides rapid identification and antibiotic susceptibility testing for bloodstream and other serious infections, addressing the same sepsis treatment-decision pathway as Presymptom.
- Cytovale: Cytovale's IntelliSep is a rapid cellular biomarker test for early sepsis diagnosis in the emergency department, a direct clinical competitor to Presymptom's earlier-detection platform.
- Inflammatix: Inflammatix builds host-response-based diagnostics to rapidly identify and differentiate infections including sepsis, overlapping directly with Presymptom's AI-driven early infection detection thesis.
- T2 Biosystems: T2 Biosystems markets T2Bacteria and T2Candida panels for rapid sepsis-causing pathogen detection, competing in the same hospital sepsis/infection diagnostics category.
Broad incumbents
- bioMérieux: bioMérieux is a large in-vitro diagnostics incumbent with extensive microbiology and sepsis-related testing products, representing the established competitive backdrop for AI-driven early infection diagnostics.
- Roche Diagnostics: Roche operates a broad diagnostics portfolio including hospital/acute care tests, setting the reference standard against which AI-driven sepsis diagnostic entrants must compete.
Others
- AbCellera: While focused on antibody discovery, AbCellera's AI-driven computational biology platform shares the AI-in-biotech R&D infrastructure profile relevant to Presymptom's machine-learning diagnostic approach.
Regional players
- Oxford Nanopore Technologies: UK-headquartered nanopore sequencing platform used in infectious disease and pathogen detection research, representing a comparable UK-based, technology-driven infectious-diagnostics peer ecosystem.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights4 records
Customer concentration
Presymptom Health social profiles
Digital presencePresymptom Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
Presymptom Health leadership team
Management profileNumber of profiles
Presymptom Health funding detail
Funding detailFunding overview
Funding rounds4 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Presymptom Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Presymptom Health
What does Presymptom Health do?
Presymptom Health developed an AI-driven diagnostics platform capable of detecting sepsis and infections up to three days before clinical symptoms manifest. The technology was based on proprietary research originating from the UK Ministry of Defence's Defence Science and Technology Laboratory (Dstl) and was targeted at hospitals, NHS trusts, and clinical healthcare settings. The company was pre-commercial with planned UK market entry in 2025.
Is Presymptom Health a public or private company?
Presymptom Health is a private company. It is classified as venture growth investor backed and is currently closed.
When was Presymptom Health founded?
Presymptom Health was founded in 2019. It employs 1 to 10 people.
Where is Presymptom Health based?
Presymptom Health is headquartered in Porton, United Kingdom, in the Europe region.
How does Presymptom Health make money?
One revenue line is on record: diagnostic Tests Platform.
Who are Presymptom Health's main competitors?
Direct peers on record are Prenosis, Dascena, Accelerate Diagnostics, Cytovale, Inflammatix and T2 Biosystems. Broad incumbents are bioMérieux and Roche Diagnostics. AbCellera is listed as an others. Oxford Nanopore Technologies is listed as a regional player.
Does Presymptom Health have an API?
No public API is recorded for Presymptom Health.
What industry is Presymptom Health in?
Presymptom Health's product category is Sepsis and Infection Diagnostics. Its primary akta.pro industry code is HLACAGAF, Sepsis, Deterioration & Rapid Response CDS, with a secondary code of HLACAGAE, Risk Stratification, Early Warning Scores & Predictive Analytics. Its NAICS code is 541714 and its SIC code is 2835.